Literature DB >> 20009126

Reversibility of liver fibrosis.

Prakash Ramachandran1, John P Iredale.   

Abstract

Liver cirrhosis is a major cause of morbidity and mortality worldwide and has very limited therapeutic options. Regardless of the aetiology, hepatic fibrosis is a characteristic feature of chronic liver disease. Our knowledge regarding the pathogenesis of this scarring has grown exponentially in the past 25 years. It has now clear that this is a highly dynamic process and the long-held dogma that it is irreversible and relentlessly progressive is now being challenged. In this review, we will summarise the key pathogenic mechanisms at play and will focus on the evidence demonstrating that liver fibrosis is reversible in humans and animal models. In particular, we will examine the role of hepatic stellate cells, MMPs, TIMPs and macrophages in this process. Finally, we will discuss some of the studies aimed to therapeutically target the resolution of fibrosis and their potential for translation into a badly-needed treatment modality in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20009126

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  35 in total

Review 1.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

Review 2.  Liver fibrosis: a bidirectional model of fibrogenesis and resolution.

Authors:  P Ramachandran; J P Iredale
Journal:  QJM       Date:  2012-05-29

3.  Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha.

Authors:  Seema S Desai; Jason C Tung; Vivian X Zhou; James P Grenert; Yann Malato; Milad Rezvani; Regina Español-Suñer; Holger Willenbring; Valerie M Weaver; Tammy T Chang
Journal:  Hepatology       Date:  2016-03-09       Impact factor: 17.425

Review 4.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 5.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

Review 6.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

Authors:  Natalie J Torok; Jonathan A Dranoff; Detlef Schuppan; Scott L Friedman
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

Review 7.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

Review 8.  Immune system modulation of kidney regeneration--mechanisms and implications.

Authors:  Hans-Joachim Anders
Journal:  Nat Rev Nephrol       Date:  2014-04-29       Impact factor: 28.314

9.  Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis.

Authors:  Bo Peng; Xueyong Huang; Ernesto S Nakayasu; John R Petersen; Suimin Qiu; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2013-03-15       Impact factor: 4.466

Review 10.  Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.